Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
Katsumi, Yoshiki
Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Feb 2008 - 1192-9 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1078-0432
10.1158/1078-0432.CCR-07-1661 doi
Antibodies, Monoclonal--pharmacology
Antibodies, Monoclonal, Humanized
Antibody-Dependent Cell Cytotoxicity
Antineoplastic Agents--pharmacology
Blotting, Western
Cell Line, Tumor
Female
Flow Cytometry
Fluorescent Antibody Technique
Humans
Immunohistochemistry
Infant
Infant, Newborn
Interleukin-2--pharmacology
Leukocytes, Mononuclear--immunology
Male
Receptor, ErbB-2--biosynthesis
Reverse Transcriptase Polymerase Chain Reaction
Rhabdoid Tumor--immunology
Trastuzumab
Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Feb 2008 - 1192-9 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1078-0432
10.1158/1078-0432.CCR-07-1661 doi
Antibodies, Monoclonal--pharmacology
Antibodies, Monoclonal, Humanized
Antibody-Dependent Cell Cytotoxicity
Antineoplastic Agents--pharmacology
Blotting, Western
Cell Line, Tumor
Female
Flow Cytometry
Fluorescent Antibody Technique
Humans
Immunohistochemistry
Infant
Infant, Newborn
Interleukin-2--pharmacology
Leukocytes, Mononuclear--immunology
Male
Receptor, ErbB-2--biosynthesis
Reverse Transcriptase Polymerase Chain Reaction
Rhabdoid Tumor--immunology
Trastuzumab